@jebus911 I mean I think that's a core issue. it's not using natural human mechanisms. Off-target effects are the real issue, swapping one heart for another is relatively simple in comparison. But they'll figure it out eventually.
@insiliconot This is nonsense. While that paper may be shit there were very good reasons to target amyloid in a time where we simply didn't have the tools to look elsewhere.
@saints_fallen @CanteringClark@austerity_sucks@cmsholdings Maybe some fields but anything biotech/pharma related US is still #1 by a huge margin. EU distant second and Asia far behind.